Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
CONCLUSIONS: The high overall and complete response levels in favorable genetic risk CLL along with favorable toxicity profiles provide rationale for consideration of a PC based strategy for previously untreated progressive CLL.
PMID: 29460654 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Fish | Genetics | Hematology | Leukemia | Rituxan | Toxicology